These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 2970967

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
    Schirrmacher V, Haas C, Bonifer R, Ertel C.
    Clin Cancer Res; 1997 Jul; 3(7):1135-48. PubMed ID: 9815793
    [Abstract] [Full Text] [Related]

  • 3. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
    Plata F, Jongeneel V, Cerottini JC, Brunner KT.
    Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
    [Abstract] [Full Text] [Related]

  • 4. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H, Yoshioka T, Shima J, Kosugi A, Itoh K, Hamaoka T.
    J Immunol; 1986 Apr 01; 136(7):2715-9. PubMed ID: 3005417
    [Abstract] [Full Text] [Related]

  • 5. The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells.
    Shimizu Y, Fujiwara H, Ueda S, Wakamiya N, Kato S, Hamaoka T.
    Eur J Immunol; 1984 Sep 01; 14(9):839-43. PubMed ID: 6236991
    [Abstract] [Full Text] [Related]

  • 6. Cell-mediated immunity to antigens associated with murine sarcoma virus-induced tumors: augmentation of cytolytic T lymphocyte activity by successive specific and nonspecific stimulation in vitro.
    Ryser JE, Cerottini JC, Brunner KT.
    Eur J Immunol; 1979 Mar 01; 9(3):179-84. PubMed ID: 221224
    [Abstract] [Full Text] [Related]

  • 7. Viral hemagglutinin augments peptide-specific cytotoxic T cell responses.
    Ertel C, Millar NS, Emmerson PT, Schirrmacher V, von Hoegen P.
    Eur J Immunol; 1993 Oct 01; 23(10):2592-6. PubMed ID: 8405059
    [Abstract] [Full Text] [Related]

  • 8. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
    Cerundolo V, Lahaye T, Horvath C, Zanovello P, Collavo D, Engers HD.
    Eur J Immunol; 1987 Feb 01; 17(2):173-8. PubMed ID: 3030766
    [Abstract] [Full Text] [Related]

  • 9. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T.
    J Immunol; 1984 Sep 01; 133(3):1671-6. PubMed ID: 6205091
    [Abstract] [Full Text] [Related]

  • 10. Cell surface expression of cytotoxic T lymphocyte-defined, AKR/Gross leukemia virus-associated tumor antigens by normal AKR.H-2b splenic B cells.
    Green WR.
    J Immunol; 1983 Dec 01; 131(6):3078-84. PubMed ID: 6605998
    [Abstract] [Full Text] [Related]

  • 11. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.
    Shimizu Y, Hasumi K, Masubuchi K, Okudaira Y.
    Eur J Immunol; 1988 Nov 01; 18(11):1773-8. PubMed ID: 2974424
    [Abstract] [Full Text] [Related]

  • 12. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
    Takai Y, Kosugi A, Yoshioka T, Tomita S, Fujiwara H, Hamaoka T.
    J Immunol; 1985 Jan 01; 134(1):108-13. PubMed ID: 3155458
    [Abstract] [Full Text] [Related]

  • 13. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells.
    Termeer CC, Schirrmacher V, Bröcker EB, Becker JC.
    Cancer Gene Ther; 2000 Feb 01; 7(2):316-23. PubMed ID: 10770642
    [Abstract] [Full Text] [Related]

  • 14. The augmentation of tumor-specific immunity by virus help. I. Demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses.
    Fujiwara H, Shimizu Y, Takai Y, Wakamiya N, Ueda S, Kato S, Hamaoka T.
    Eur J Immunol; 1984 Feb 01; 14(2):171-5. PubMed ID: 6199215
    [Abstract] [Full Text] [Related]

  • 15. Generation of cytotoxic T lymphocytes in vitro. VI. Effect of cell density on response in mixed leukocyte cultures.
    Fitch FW, Engers HD, MacDonald HR, Cerottini JC, Brunner KT.
    J Immunol; 1975 Dec 01; 115(6):1688-94. PubMed ID: 127012
    [Abstract] [Full Text] [Related]

  • 16. Primary and secondary in vitro generation of cytolytic T lymphocytes in the murine sarcoma virus system.
    Plata F, Cerottini JC, Brunner KT.
    Eur J Immunol; 1975 Apr 01; 5(4):227-33. PubMed ID: 185057
    [Abstract] [Full Text] [Related]

  • 17. Generation of virus specific cytotoxic T cells in vitro. III. Spleen cells stimulated by viral antigens generate alloreactive cytotoxic T cells.
    Koszinowski U, Greber D, Neuschaefer-Rube I.
    Immunobiology; 1979 Aug 01; 156(1-2):83-95. PubMed ID: 232074
    [Abstract] [Full Text] [Related]

  • 18. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta.
    von Hoegen P, Zawatzky R, Schirrmacher V.
    Cell Immunol; 1990 Mar 01; 126(1):80-90. PubMed ID: 2302742
    [Abstract] [Full Text] [Related]

  • 19. The immune response of the mouse to lymphocytic choriomeningitis virus. V. High numbers of cytolytic T lymphocytes are generated in the spleen during acute infection.
    Moskophidis D, Assmann-Wischer U, Simon MM, Lehmann-Grube F.
    Eur J Immunol; 1987 Jul 01; 17(7):937-42. PubMed ID: 2886344
    [Abstract] [Full Text] [Related]

  • 20. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH, Daynes RA, Hodes RJ.
    J Immunol; 1986 Feb 15; 136(4):1521-7. PubMed ID: 2418117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.